Top Tweets for #CFS24

over 1 year ago

With what @Dr_Aggen described as a “sea change” having occurred in the frontline treatment of urothelial carcinoma, providers are facing the issue of how to best tailor therapy for individual patients. @MSKCancerCenter @gotoPER #CFS24 Read here: https://t.co/VhybzIA5Lg

0

2

1

0

736

over 1 year ago

And that's a wrap on #CFS24! Huge thank you to everyone who presented, attended, and came to speak with us these past 3 days. Missed a presentation, or just want to learn more? Visit our website for more insights, interviews, and information. @gotoPER #gotoPER #oncology

OncLive's tweet photo. And that's a wrap on #CFS24! Huge thank you to everyone who presented, attended, and came to speak with us these past 3 days. Missed a presentation, or just want to learn more? Visit our website for more insights, interviews, and information. @gotoPER #gotoPER #oncology https://t.co/fSoIsFVM5G

0

3

0

789

over 1 year ago

Learning from Drs. @ZPiotrowskaMD @Annechiangmd and Erminia Massarelli at #CFS24!

0

6

0

1K

over 1 year ago

Another fantastic interview with Michael A. Postow, MD, of @MSKCancerCenter is in the books. To hear Dr Postow expand on hot topics and unanswered questions in melanoma, check back on our site at: https://t.co/XYrgP2P0c8 @gotoPER #gotoPER #CFS24 #melsm

OncLive's tweet photo. Another fantastic interview with Michael A. Postow, MD, of @MSKCancerCenter is in the books. To hear Dr Postow expand on hot topics and unanswered questions in melanoma, check back on our site at: https://t.co/XYrgP2P0c8 @gotoPER #gotoPER #CFS24 #melsm https://t.co/g1FSnlgskF

0

4

0

739

over 1 year ago

Dr. @ChaftJamie at #CFS24 reminds us how poor outcomes are even with early stage NSCLC. The storm of new approvals is translating to better outcomes. Huge impact of perioperative immunotherapy for driver negative, postoperative TKIs for EGFR/ALK NSCLC. Important to test here!

StephenVLiu's tweet photo. Dr. @ChaftJamie at #CFS24 reminds us how poor outcomes are even with early stage NSCLC. The storm of new approvals is translating to better outcomes. Huge impact of perioperative immunotherapy for driver negative, postoperative TKIs for EGFR/ALK NSCLC. Important to test here! https://t.co/1MEG4gl5Ry

0

15

2

8

1K

over 1 year ago

We're right back at it with some fantastic presentations on ADCs in NSCLC and the evolving role of immunotherapy during this afternoon's lung cancer session at #CFS24! Follow along for more real-time updates! @gotoPER #gotoPER #lcsm #oncology

OncLive's tweet photo. We're right back at it with some fantastic presentations on ADCs in NSCLC and the evolving role of immunotherapy during this afternoon's lung cancer session at #CFS24! Follow along for more real-time updates! @gotoPER #gotoPER #lcsm #oncology https://t.co/zVHJlpzO7u

0

3

1

0

1K

over 1 year ago

Dr. @PatelOncology at #CFS24 discusses the current best practice with immunotherapy for NSCLC. Many different options but some common themes. Will ivonescimab change the field?

StephenVLiu's tweet photo. Dr. @PatelOncology at #CFS24 discusses the current best practice with immunotherapy for NSCLC. Many different options but some common themes. Will ivonescimab change the field? https://t.co/ulDPiSCS08

0

19

4

3

2K

over 1 year ago

The inimitable Dr. @MLJohnsonMD2 at #CFS24 updates us on ADCs. Dato-DXd now being explored in previously treated #EGFR NSCLC. How will we use the new emerging biomarker approaches? New molecules emerging look very encouraging!

StephenVLiu's tweet photo. The inimitable Dr. @MLJohnsonMD2 at #CFS24 updates us on ADCs. Dato-DXd now being explored in previously treated #EGFR NSCLC. How will we use the new emerging biomarker approaches? New molecules emerging look very encouraging! https://t.co/1BoYxjXoLU

2

26

3

9

2K

over 1 year ago

A huge thank you to @PatelOncology of @UCSDHealth for stopping by to discuss the evolution of immunotherapy and targeted therapy in NSCLC. To learn more about this and many more presentations from #CFS24, visit: https://t.co/XYrgP2Py1G @gotoPER #gotoPER #lcsm

OncLive's tweet photo. A huge thank you to @PatelOncology of @UCSDHealth for stopping by to discuss the evolution of immunotherapy and targeted therapy in NSCLC.

To learn more about this and many more presentations from #CFS24, visit: https://t.co/XYrgP2Py1G

@gotoPER #gotoPER #lcsm https://t.co/DIW5J0EU7C

0

9

1

904

over 1 year ago

Dr. @RielyMD at #CFS24 highlights treatment for NSCLC with #BRAF V600E (dabrafenib + trametinib, encorafenib + binimetinib), #MET exon 14 (capmatinib, tepotinib), and #KRAS G12C (1L IO based therapy, 2L sotorasib, adagrasib).

StephenVLiu's tweet photo. Dr. @RielyMD at #CFS24 highlights treatment for NSCLC with #BRAF V600E (dabrafenib + trametinib, encorafenib + binimetinib), #MET exon 14 (capmatinib, tepotinib), and #KRAS G12C (1L IO based therapy, 2L sotorasib, adagrasib). https://t.co/70REfXmwVV

1

26

8

3

4K

over 1 year ago

A treat to hear about novel therapeutic frontiers in fusion positive NSCLC from Dr. Alice Shaw at #CFS24. Profound efficacy with targeted agents for #ALK #ROS1 #RET fusion positive NSCLC - critical to identify these fusions when present. Exciting new drugs coming!

StephenVLiu's tweet photo. A treat to hear about novel therapeutic frontiers in fusion positive NSCLC from Dr. Alice Shaw at #CFS24. Profound efficacy with targeted agents for #ALK #ROS1 #RET fusion positive NSCLC - critical to identify these fusions when present. Exciting new drugs coming! https://t.co/0gm81dVdEO

2

45

19

11

5K

Kelly Mercier, Ph.D @KellyMercierPh1

over 1 year ago

Dr. @ZPiotrowskaMD at #CFS24 discusses the suddenly complex first line space for #EGFR NSCLC with approvals for osimertinib alone (FLAURA), osimertinib plus chemotherapy (FLAURA2), and amivantamab plus lazertinib (MARIPOSA). Need to learn who benefits most from each approach.

StephenVLiu's tweet photo. Dr. @ZPiotrowskaMD at #CFS24 discusses the suddenly complex first line space for #EGFR NSCLC with approvals for osimertinib alone (FLAURA), osimertinib plus chemotherapy (FLAURA2), and amivantamab plus lazertinib (MARIPOSA). Need to learn who benefits most from each approach. https://t.co/jAzZJvzkj2

0

16

0

3

2K

over 1 year ago

I’m happy to be jumping into #cfs24 with the #LungCancer session. Thank you, @ZPiotrowskaMD, for highlighting that we need to track not only which gene has mutations but what kind of mutation and where.

KellyMercierPh1's tweet photo. I’m happy to be jumping into #cfs24 with the #LungCancer session. Thank you, @ZPiotrowskaMD, for highlighting that we need to track not only which gene has mutations but what kind of mutation and where. https://t.co/f7dnsC9Qn0

0

9

1

0

825

over 1 year ago

Dr. @benlevylungdoc kicks off the lung cancer block of #CFS24 with a great faculty lineup ahead!

1

10

1

1K

over 1 year ago

Our final day of #CFS24 coverage has officially begun, with some great sessions on urothelial being held this morning! We can’t wait to see what other amazing presentations it brings. Keep follow following along for more conference updates! @gotoPER #gotoPER #oncology #medtwitter

OncLive's tweet photo. Our final day of #CFS24 coverage has officially begun, with some great sessions on urothelial being held this morning! We can’t wait to see what other amazing presentations it brings. Keep follow following along for more conference updates! @gotoPER #gotoPER #oncology #medtwitter https://t.co/jIyb9ZWXg1

0

3

1

0

534